AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): An oral formulation for gastrointestinal drug delivery which comprises an adhesion site-controlling layer for attaching the formulation to a selected site in the intestines, a drug-carrying layer containing a drug and an adhesive to attach the drug containing layer to the selected site in the intestines when the adhesion site-controlling layer dissolves at the selected site in the intestines, and a protecting layer ~~or protecting the drug in the drug-carrying layer~~ structured and arranged for preventing digestive juice from permeating into the drug-carrying layer and the drug-carrying layer from releasing the drug through the protecting layer, the drug-carrying layer existing between the protecting layer and the adhesion site-controlling layer, the adhesion site--controlling layer may attach to the protecting layer and the adhesion site-controlling layer is a film made of an enteric polymer, and the adhesion site-controlling layer contains a plasticizer.

2. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein each of the adhesion site-controlling layer, the drug-carrying layer and the protecting layer is in the form of film, and said three layers are laminated.

3. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 2 wherein each of the adhesion site-controlling layer, the drug-carrying layer and the protecting layer has a thickness of from 20 to 100 μm.

4. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the protecting layer is in hemispherical form forming an inner space and an opening part, and the drug-carrying layer exists in the inner space of the protecting layer in said hemispherical form, and wherein the adhesion site-controlling layer covers the opening part of the protecting layer in said hemispherical form.

5. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 4 wherein the hemisphere has an inside depth from 50 to 500 μm, the opening part of the hemisphere has an inside diameter of from 20 to 800 μm, and each of the protecting layer and the adhesion site-controlling layer has a thickness of from 20 to 100 μm.

6. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer is a porous sheet substrate soaked with a drug, or a sheet or a film of a gel or a wax which contains a drug.

7. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer further contains one or more ingredients selected from the group consisting of absorption promoters, protease inhibitors and transporter inhibitors.

8. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the protecting layer is a film or a capsule, each of said film or capsule being composed of at least one of a water-insoluble polymer and a wax.

9. (Canceled)

10. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug is a physiologically active protein or peptide.

11. (Original): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug is G-CSF, interferon or indinavir.

12. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 1 in a capsule.

13. (Original): The oral capsule formulation according to claim 12 which is an enteric capsule.

14. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 2 in a capsule.

15. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 4 in a capsule.

16. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 6 in a capsule.

17. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 7 in a capsule.

18. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 8 in a capsule.

19. (Canceled)

20. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 10 in a capsule.

21. (Previously Presented): An oral capsule formulation which is prepared by filling the formulation according to claim 11 in a capsule.

22. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the adhesion site-controlling layer is attached to the protecting layer.

23. (Previously Presented): The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer is sealed between the adhesion site--controlling layer and the protecting layer to prevent leaking of the drug.

24. (Previously Presented): The oral capsule formulation according to claim 14 which is an enteric capsule.

25. (Previously Presented): The oral capsule formulation according to claim 15 which is an enteric capsule.